Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
Workman
P
P
MRC Clinical Oncology Unit, Medical Research Council Centre, Cambridge, U.K.
Donaldson
J
J
Lohmeyer
M
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism; D010742:Phospholipid Ethers / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014230:Triazoles / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D001381:Azepines; D005663:Furans; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D014230:Triazoles; C052518:WEB 2086; C055462:SRI 62-834; C026659:edelfosine; D002118:Calcium